CS
LRMR icon

Credit Suisse’s Larimar Therapeutics LRMR Stock Holding History

Credit Suisse’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-879
Closed -$29K – 4190
2019
Q1 		$29K Buy
+879
New +$45.1K ﹤0.01% 3925
2018
Q4 		– Sell
-1,659
Closed -$233K – 3955
2018
Q3 		$233K Sell
1,659
-934
-36% -$113K ﹤0.01% 3614
2018
Q2 		$319K Buy
+2,593
New +$220K ﹤0.01% 3607
2017
Q3 		– Sell
-5,585
Closed -$235K – 4230
2017
Q2 		$235K Buy
+5,585
New +$286K ﹤0.01% 3572
2017
Q1 		– Sell
-3,205
Closed -$122K – 3954
2016
Q4 		$122K Buy
3,205
+2,130
+198% +$86.4K ﹤0.01% 3916
2016
Q3 		$42K Sell
1,075
-2,195
-67% -$99.7K ﹤0.01% 4031
2016
Q2 		$234K Buy
3,270
+1,043
+47% +$82.4K ﹤0.01% 3800
2016
Q1 		$178K Sell
2,227
-2,365
-52% -$187K ﹤0.01% 3718
2015
Q4 		$346K Buy
4,592
+3,853
+521% +$619K ﹤0.01% 3615
2015
Q3 		$284K Sell
739
-3,366
-82% -$1.52M ﹤0.01% 3752
2015
Q2 		$1.71M Buy
4,105
+1,993
+94% +$834K ﹤0.01% 2677
2015
Q1 		$1M Buy
2,112
+1,368
+184% +$649K ﹤0.01% 2970
2014
Q4 		$275K Buy
+744
New +$192K ﹤0.01% 4103

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Credit Suisse's LRMR Position: Q2 2019 in Review

Credit Suisse sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 879 shares — an estimated $29K sold.

Credit Suisse first reported a position in LRMR in Q4 2014 and held it in 13 quarters. The position peaked at $1.71M in Q2 2015. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

  • Credit Suisse reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Credit Suisse sold 879 Larimar Therapeutics shares in Q2 2019, an estimated $29K.
  • Credit Suisse first reported a position in Larimar Therapeutics in Q4 2014 and held it in 13 quarters.
  • Credit Suisse's Larimar Therapeutics position peaked at $1.71M in Q2 2015.
  • 71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.